Generation Capital Management’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$510K Buy
15,630
+4,000
+34% +$139K 0.31% 62
2026
Q2
$454K Hold
11,630
– – 0.28% 65
2026
Q1
$378K Buy
11,630
+2,000
+21% +$64.3K 0.28% 59
2025
Q4
$339K Hold
9,630
– – 0.22% 70
2025
Q3
$253K Hold
9,630
– – 0.18% 70
2025
Q2
$255K Buy
+9,630
New +$254K 0.2% 68

Other funds holding VKTX

Generation Capital Management's VKTX Position: Q3 2026 in Review

Generation Capital Management increased its Viking Therapeutics (VKTX) stake by 34% in Q3 2026, buying an estimated $139K and bringing the position to 15,630 shares worth $510K. The position accounts for 0.31% of the portfolio, ranked #62.

Generation Capital Management first reported a position in VKTX in Q2 2025 and has held it in 6 quarters since. 444 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Generation Capital Management held 15,630 shares of Viking Therapeutics worth $510K as of Q3 2026.
  • Generation Capital Management bought 4,000 Viking Therapeutics shares in Q3 2026, an estimated $139K.
  • Viking Therapeutics made up 0.31% of Generation Capital Management's portfolio in Q3 2026, its #62 holding.
  • Generation Capital Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 444 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Generation Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.